Document Type
Article
Publication Date
11-1-2021
Abstract
PURPOSE/OBJECTIVE(S): To evaluate the clinical role of temozolomide rechallenge (TMZ) in patients with recurrent high-grade glioma (HGG) treated with re-irradiation (re-RT) regardless of surgical status. MATERIALS/METHODS: Single-center retrospective review of patients with a primary diagnosis of World Health Organization (WHO) Grade III anaplastic astrocytoma or Grade IV GBM treated from 2008 to 2016 for disease recurrence with re-RT (35 Gy in 10 fractions) with and without temozolomide rechallenge. Baseline characteristics were analyzed with pairwise tests. OS/PFS were assessed with the Kaplan-Meier method and multivariable cox regression models for OS. RESULTS: Two hundred and thirty patients were treated with re-irradiation (n = 67 with and n = 163 without concurrent TMZ), with a median follow-up of 13.4 months. Baseline characteristics were similar between the two groups. TMZ rechallenge did not improve OS (HR 0.81 [0.51-1.3] P = 0.39). Univariate regression analysis showed that higher KPS both at diagnosis and recurrence correlated with improved survival, whereas increasing histology grade of initial and recurrent disease and volume of recurrence were correlated with worse OS. Multivariate regression analysis showed primary tumor location to be a significant predictor of OS (P = 0.004) with occipital lobe lesions (P < 0.001) and in-field recurrence (P < 0.001) to be most favorably correlated with OS. CONCLUSION: TMZ rechallenge in patients with recurrent HGG treated with re-irradiation offered no survival benefit. Our findings suggest that patient selection may be important in TMZ rechallenge. Further studies in identifying this group of patients are warranted.
Recommended Citation
Basree, Mustafa; Ali, Ayesha; Garg, Shivank; Glass, Jonathan; Kim, Lyndon; Farrell, Christopher J; Evans, James J.; Judy, Kevin; Andrews, David W.; Shi, Wenyin; Werner-Wasik, Maria; and Palmer, Joshua, "Temozolomide Rechallenge in Patients With Recurrent High-Grade Glioma Treated With Re-Irradiation" (2021). Department of Neurosurgery Faculty Papers. Paper 170.
https://jdc.jefferson.edu/neurosurgeryfp/170
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Language
English
Comments
This article is the author’s final published version in International journal of radiation oncology, biology, physics, Volume 111, Issue 3, November 2021, Pages e587 - e588.
The published version is available at https://doi.org/10.1016/j.ijrobp.2021.07.1574. Copyright © Published by Elsevier Inc.